Paper
11beta-hydroxysteroid dehydrogenases: changing glucocorticoid action.
Published Dec 1, 2004 · J. Seckl
Current opinion in pharmacology
Q1 SJR score
183
Citations
5
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Highly CitedStudy Snapshot
11beta-HSD1 overexpression may contribute to metabolic syndrome and its inhibition may be a potential therapeutic target for metabolic and glucocorticoid-associated CNS disorders.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Down-regulation of adipose 11beta-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease.
Chronic high-fat feeding in mice leads to a lower adipose 11beta-HSD-1 set point, potentially providing metabolic protection and counteracting metabolic disease.
2004·126citations·N. Morton et al.·Endocrinology
Endocrinology
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Elevated hepatic expression of 11beta-HSD1 may contribute to the pathogenesis of specific fatty liver, insulin-resistant, and hypertensive syndromes without obesity in humans.
2004·471citations·J. Paterson et al.·Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America
Ontogeny of glucocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type-1 gene expression identifies potential critical periods of glucocorticoid susceptibility during development.
The ontogeny of glucocorticoid receptor and 11beta-HSD1 genes suggests potential critical periods of glucocorticoid sensitivity during development for various organ systems.
2004·143citations·H. Speirs et al.·The Journal of endocrinology
The Journal of endocrinology
Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice.
11 beta-HSD-1 deficiency in adipose tissue improves insulin sensitivity and resistance to visceral obesity in mice, potentially benefiting metabolic health.
2004·550citations·N. Morton et al.·Diabetes
Diabetes
Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains.
Selective 11 beta-HSD1 inhibitors lower blood glucose levels and improve insulin sensitivity in various mouse models of type 2 diabetes.
2003·273citations·P. Alberts et al.·Endocrinology
Endocrinology
Citations
Glucocorticoids influence on rat hematological parameters and catalase activity.
Betamethasone dipropionate administration can alter hematological parameters in rats, emphasizing the need for cautious corticosteroid administration.
2024·0citations·S. Herenda et al.·Frontiers in pharmacology
Frontiers in pharmacology
Effects of gestational age on blood cortisol and prolactin levels during pregnancy in malaria endemic area
Gender differences in pregnancy hormone levels contribute to the risk of miscarriage, with higher cortisol levels in primigravidae and lower prolactin levels in multigravidae.
2024·0citations·Francois Kiemde et al.·PLOS ONE
PLOS ONE
Age-related increase in the expression of 11β-hydroxysteroid dehydrogenase type 1 in the hippocampus of male rhesus macaques
An age-related increase in hippocampal HSD11B1 expression may contribute to increased cortisol levels in the brain, contributing to neuronal loss and dementia in the elderly.
2024·1citation·Alejandro Lomniczi et al.·Frontiers in Aging Neuroscience
Frontiers in Aging Neuroscience
Can Resveratrol Influence the Activity of 11β-Hydroxysteroid Dehydrogenase Type 1? A Combined In Silico and In Vivo Study
Resveratrol can reduce 11-HSD-1 activity in the liver, potentially improving cortisol levels and reducing anxiety in stressed and non-stressed animals.
2023·5citations·Jurica Novak et al.·Pharmaceuticals
Pharmaceuticals
Cardiac Hypertrophy and Related Dysfunctions in Cushing Syndrome Patients—Literature Review
Cardiac hypertrophy and related dysfunctions in Cushing syndrome patients remain a major risk factor, with treatment effects varying for structural alterations and functional disorders.
2022·4citations·Akinori Kanzaki et al.·Journal of Clinical Medicine
Journal of Clinical Medicine
11β-Hydroxysteroid Dehydrogenase Type 1 as a Potential Treatment Target in Cardiovascular Diseases
Selective inhibition of 11-HSD1 may offer a potential treatment target for obesity, metabolic syndrome, and cardiovascular complications.
2022·6citations·D. Kupczyk et al.·Journal of Clinical Medicine
Journal of Clinical Medicine